GenSight Biologics S.A. (EPA:SIGHT)

Market Cap	17.40M -48.0%
Revenue (ttm)	945.00K -52.2%
Net Income	-15.12M
EPS	-0.13
Shares Out	220.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	614,453
Average Volume	1,591,991
Open	0.0790
Previous Close	0.0828
Day's Range	0.0780 - 0.0810
52-Week Range	0.0752 - 0.3190
Beta	0.89
RSI	35.83
Earnings Date	Mar 26, 2026

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 13
• Stock Exchange: Euronext Paris
• Ticker Symbol: SIGHT

Financial Performance

In 2024, GenSight Biologics's revenue was 2.63 million, a decrease of -11.44% compared to the previous year's 2.96 million. Losses were -14.00 million, -46.60% less than in 2023.